Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. - Qin S; Chen M; Cheng AL; Kaseb AO; Kudo M; Lee HC; Yopp AC; Zhou J; Wang L; Wen X; Heo J; Tak WY; et al. (Lancet (London, England), 2023)